Brief #94607Updated 18 NOV 2025SAN MATEOGVSERIES A
Employbl DossierEpiBiologics
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
- Founded
- 2022
- Headcount
- 31
- Open roles
- 0
- Last raised
- Series A · $23M
Section II — RestrictedMembers only
- Engineering interview process at EpiBiologics
- Tech stack & infrastructure choices
- Culture & day-to-day work style
- Why join now vs. 6 months from now
- Hiring focus & open headcount by team
- Comp philosophy and band context
7-day free trial · $25/mo · cancel anytime
